He is considered one of the most relevant oncologists due to his greatest international contributions in cancer research
Dr. Javier Cortés Castán
Dr. Javier Corte?s Casta?n is a renowned professional, specialized in Medical Oncology, dedicated to the treatment of patients with breast cancer, exclusively. He is considered one of the most relevant oncologists with the greatest international contributions in oncological research, especially in the field of breast tumors, leading numerous international clinical trials in this pathology.
Graduated in Medicine and Surgery from the Autonomous University of Madrid in 1996 , he took the specialty of Medical Oncology at the University of Navarra, Dr. Corte?s is the founder and director of the International Breast Cancer Center (IBCC), the first center in Spain that covers all aspects related to the prevention and treatment of breast cancer. It is a monographic breast oncology center, which operates independently and is made up of a group of specialists with more than 20 years of experience: oncologists, pathologists, radiologists, psycho-oncologists, nurses, clinical assistants, management and patient care team make up this team of excellence of the IBCC. In addition, each of its members is hyperspecialized in the approach to breast cancer, with an excellent medical-scientific and human practice, treating the disease from research, prevention, diagnosis and treatment, without forgetting the comprehensive care of patients, mostly women. In this sense, the IBCC considers that "the management of breast cancer includes not only the clinical approach to the disease, but also many other aspects that must be taken into account, such as the emotional situation, nutrition or physical activity. If properly observed, they can positively impact the evolution of the disease."
"With real passion for the treatment of his patients, very sensitive by the people affected, to whom he approaches in a very careful way, always seeking the improvement of their experience and quality of life". This is how those who know Dr. Javier Corte?s define him.
Dr. Corte?s is director of the Breast Cancer Program of the Institute of Oncology of the Ruber Hospitals of Madrid, and coordinator of the Breast Cancer Unit of the oncology services of the Hospitals of the Ribera Salud Group (Torrejo?n, Vinalopo? and Povisa) as well as founding partner of Medica Scientia Innovation Research (MedSIR). He is a clinical researcher of the Breast Cancer Research Program at the Vall d'Hebron Institute of Oncology in Barcelona.
Dr. Corte?s has actively participated in the development of 9 drugs approved for metastatic breast cancer in Europe in recent years, leading with his group, the trials that led to the approval of several of these agents: pertuzumab, bevacizumab, eribulin, sacituzumab, margetuximab, pembrolizumab and trastuzumab deruxtecan, among others. He is very committed and involved in research against this tumor, especially in the triple negative and HER2-positive subtypes, thus being able to contribute to optimizing the prognosis of these patients. In the words of the doctor "the prognosis of these patients is infinitely better than 10 or 15 years ago. If then 60-70% of patients were cured, today more than 80% do. Even when there are metastases and the tumor cannot be cured, sometimes these patients can live for many years and sometimes even chronify the disease."
The doctor is part of more than 150 scientific projects related to this disease, with a leading position in many of them, in addition to directing some of the most important trials worldwide in the field of metastatic breast cancer.
Dr. Javier Corte?s Casta?n, is the author of some 330 international publications, especially on breast cancer, being the only Spanish to have three publications in the CA journal: a Cancer Journal for Clinicians, the medical journal with the highest impact factor in the world. He has also presented more than 800 conferences at different international congresses and is a reviewer of medical journals of the highest level, such as New England Journal of Medicine, Lancet, Lancet Oncology, Annals of Oncology, Nature Medicine, Cancer Cell or Journal of Clinical Oncology,among manyothers.
He is also an active member of the Spanish, European and American Medical Oncology Societies (SEOM, ESMO, ASCO). In addition, he is a member of the Scientific Committee of the European Society of Medical Oncology (ESMO), has been chair for breast cancer at the ESMO 2020 congress, and co-chair of the same section at the American Association for Cancer Research (AACR) 2020 congress as well as the immunotherapy area of the AACR 2021 congress. Member of the panel of experts who develop the treatment guidelines for metastatic breast cancer of the European Society of Medical Oncology.
